Experimental ADC shows promising initial activity in head and neck cancers
UT MD Anderson News Release November 18, 2026
- Micvotabart pelidotin (MICVO, PYX-201) is an experimental antibody drug conjugate (ADC) from Pyxis Oncology that holds an FDA Fast Track Designation in this setting
- In a Phase 1 trial of heavily pretreated patients with head and neck cancers, MICVO achieved a confirmed 39% overall response rate and 6.7-month median progression-free survival
- Historical response rates to the standard of care in this setting are around 15%, with progression typically occurring in less than two months
- These data have prompted a Phase 3 trial, expected to begin in 2027
ABSTRACT LBA3
The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase 1 trial presented by researchers at The University of Texas MD Anderson Cancer Center.
The study evaluated MICVO in patients with recurrent or metastatic head and neck squamous cell carcinoma who had progressed after prior therapies, a setting where historical response rates are approximately 15%. Among 33 efficacy-evaluable patients, MICVO achieved a confirmed overall response rate of 39%, including one complete response. Median progression-free survival was 6.7 months, and the one-year overall survival rate was 81%. Responses were observed regardless of HPV status or prior treatment history. The data were presented today by principal investigator Faye Johnson, M.D., Ph.D., professor of Head & Neck Medical Oncology, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
“These results are encouraging because patients with recurrent or metastatic head and neck cancer have very limited treatment options once their disease progresses after initial therapy, and the treatments currently available are effective for only a small proportion of patients,” Johnson said. “This is a substantial unmet need, affecting approximately 20,000 patients each year in the U.S., and these findings suggest micvotabart pelidotin may offer a promising new option for this population.”
How does MICVO work to treat cancer?
MICVO works by binding to a specific target in the scaffolding of the tumor that surrounds the cancer cells known as extradomain-B of fibronectin, which allows MICVO to release a therapeutic payload directly to a tumor. Extradomain-B of fibronectin can be found in very high levels in the extracellular matrix of tumors, but is uncommon in normal tissue, making it a good candidate for targeting by ADCs.
MICVO carries a payload of auristatin-0101, a chemotherapy-type drug that disrupts the cell division process, killing the cells.
What were other findings of this MICVO trial?
This trial enrolled 36 patients with either recurrent or metastatic head and neck squamous cell carcinoma, and 33 were able to be evaluated for the effectiveness of treatment.
Adverse effects in this trial were consistent with previously recorded side effects of auristatins. Approximately half of the patients experienced at least one treatment-related grade 3 adverse effect, but most were manageable and reversible. Adverse effects occurring in more than 10% of patients included fatigue, nerve damage in the hands and feet, joint pain, nausea, rash and changes in red blood cell counts. Six patients had more serious nerve damage that arose at a median of five and a half months of treatment. The symptoms improved in all six patients after dose adjustments with five of the six patients improving to asymptomatic, minimally symptomatic or better.
What’s next for this therapy?
A Phase 3 trial is set to begin in 2027 to evaluate MICVO as a monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma who have had at least one prior systemic treatment. Another Phase 2 trial is underway testing it in combination with pembrolizumab.
***
This trial was funded by Pyxis Oncology. A full list of authors and their disclosures can be found with the abstract.
This is a substantial unmet need, affecting approximately 20,000 patients each year in the U.S., and these findings suggest micvotabart pelidotin may offer a promising new option for this population.